Tumor-bearing, humanized NSG™ mice are a new and valuable preclinical testing platform for immuno-oncology, to simulate trials, evaluate multiple drugs alone or in combination, and produce predictive data.

NSG™ mice are a proven host for engraftment of human tumors as well as the establishment of human immunity following hematopoietic stem cell transplantation. Tumor-bearing humanized NSG™ mice represent a ground-breaking immunotherapeutic evaluation platform to address outstanding questions in the rapidly advancing field of immuno-oncology:

  1. Which tumor types will be most responsive to immunotherapy and what are the underlying mechanisms?
  2. How can optimal therapy combinations be determined for individual patients?
  3. What are the mechanisms behind resistance to immunotherapy and immunomodulatory agents?
  4. How can resistance be anticipated and prevented?

Leveraging the robust engraftment of functional human immune cells and the capability of co-engrafting patient-derived tumors from a selection of over 300 PDX models in humanized mice,  this platform has the potential to overcome existing challenges with evaluating antibody-based therapeutics in syngeneic mouse models.